AL Amyloidosis
60
21
27
19
Key Insights
Highlights
Success Rate
76% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
10.0%
6 terminated out of 60 trials
76.0%
-10.5% vs benchmark
10%
6 trials in Phase 3/4
47%
9 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (60)
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
A Registry of AL Amyloidosis (ReAL)
A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
Evaluation of Skin Tests in Biotherapy Allergies
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
BE.Amycon Biobank & Data Registry UZ Leuven